Agree we need P2 to maximise any deal and timeline is years off so patience is required. That’s what the Cosela (example) and Race trial timeframes / triangle report suggest.
P1 results will give insight into proof of concept for CPACS and thus a ‘major’ turning point in the development of RC220.
If you think P1 is ONLY a safety trial then think again. If CPACS isn’t present in P1 then I’m doubtful P2/P3
would show otherwise.
This is due to the way Cardio protection and FTO inhibition work.
Agree we need P2 to maximise any deal and timeline is years off...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.005(0.34%) |
Mkt cap ! $242.5M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.50 | $1.43 | $62.91K | 43.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5700 | $1.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 591 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.46 |
Change
-0.005 ( 0.23 %) |
||||
| Open | High | Low | Volume | ||
| $1.44 | $1.49 | $1.43 | 9034 | ||
| Last updated 13.08pm 24/05/2024 ? | |||||
| RAC (ASX) Chart |